Randomized trial · people
Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes, this trial found that a once-daily orforglipron pill led to more weight loss than placebo over 72 weeks, with larger losses at higher doses and gut problems as the main side effects that led people to stop.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1613
- Published
- 2026
- Journal
- Lancet
What they tested
The team tested whether orforglipron, a once-daily GLP-1 receptor agonist pill that is not a peptide, helps adults with type 2 diabetes and excess weight lose weight over 72 weeks.
How the study was done
A phase 3, double-blind, randomized, placebo-controlled trial run at 136 sites. It enrolled 1613 adults with type 2 diabetes whose BMI was at least 27 kg/m2 and whose HbA1c (a 3-month average of blood sugar) sat between 7% and 10%. Each person took orforglipron 6 mg, 12 mg or 36 mg, or a placebo (a dummy pill), every day for 72 weeks along with lifestyle changes.

Model. Individual results vary.
What they found
Average body weight changed by -5.1% in the 6 mg arm, -7.0% in the 12 mg arm and -9.6% in the 36 mg arm, compared with -2.5% on placebo (all p<0.0001). These results count every randomized person, including those who stopped treatment. HbA1c and all other planned weight and heart-and-metabolism measures improved significantly with orforglipron. The most common side effects were mild-to-moderate stomach and gut problems, mostly while the dose was being stepped up, and 6.1-9.9% of people on orforglipron stopped because of side effects, compared with 4.1% on placebo.
What it doesn’t show
The trial only included adults with type 2 diabetes and an HbA1c of 7-10%, so it does not show results in people without diabetes, and all groups also made lifestyle changes. The study was funded by Eli Lilly and Company.
The paper
Horn et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2026.
The compound
More studies on Orforglipron
- Orforglipron: heart events no worse than insulin in ACHIEVE-4Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1Randomized trial · people · 2025
- Orforglipron: food lowered drug exposure by 17.6% to 23.7%Clinical trial · people · 2024
- Every study on Orforglipron
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.